PFO
INO icon

Pioneer Family Office’s Inovio Pharmaceuticals INO Stock Holding History

Pioneer Family Office’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$320 Hold
291
– – ﹤0.01% 128
2026
Q1 		$506 Hold
291
– – ﹤0.01% 121
2025
Q4 		$506 Buy
+291
New +$641 ﹤0.01% 136

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pioneer Family Office's INO Position: Q2 2026 in Review

Pioneer Family Office held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 291 shares worth $320. The position accounts for ﹤0.01% of the portfolio, ranked #128.

Pioneer Family Office first reported a position in INO in Q4 2025 and has held it in 3 quarters since. The position peaked at $506 in Q1 2026. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Pioneer Family Office held 291 shares of Inovio Pharmaceuticals worth $320 as of Q2 2026.
  • Pioneer Family Office left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Pioneer Family Office's portfolio in Q2 2026, its #128 holding.
  • Pioneer Family Office first reported a position in Inovio Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Pioneer Family Office's Inovio Pharmaceuticals position peaked at $506 in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Pioneer Family Office's 13F filing for Q2 2026, filed 28 Jul 2026.